2019
Karo Pharma acquires product portfolio from LEO Pharma
Karo Pharma acquires a focused intimate care and dermatology product portfolio from the Danish pharmaceutical company LEO Pharma for 90…
Åsa Riisberg leaves the Board of Directors of Karo Pharma at her own request
Åsa Riisberg has notified the Board of Directors of Karo Pharma that she, due to a number of time-consuming commitments,…
Karo Pharma divests Hydrokortison Trimb to Evolan Pharma
As previously communicated, Karo Pharma Aktiebolag (“Karo Pharma”) voluntarily and within a certain time undertook to divest Hydrokortison Trimb and…
Further clarification regarding the ROR-gamma project
On November 5, 2019, Karo Pharma Aktiebolag (“Karo Pharma”) issued a press release regarding the Pfizer collaboration and license agreement…
Interim report January – September 2019
JULY – SEPTEMBER · Net sales amounted to MSEK 443.7 (395.3). This corresponds to an increase of 12% for the…
Termination of project regarding ROR-gamma
In December 2011, Karo Pharma Aktiebolag (”Karo Pharma”) entered into a research collaboration and license agreement with Pfizer, with the…
New number of shares and votes in Karo Pharma
As previously announced, Karo Pharma Aktiebolag (“Karo Pharma”) has completed a rights issue of 60,700,422 shares, with the purpose of…
Karo Pharma’s rights issue fully subscribed
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South…
Karo Pharma postpones publication of the interim report for the period January – September 2019
The board of directors of Karo Pharma Aktiebolag (”Karo Pharma”) has resolved to postpone the publication of the interim report…